Physician profile
Mark Adelman
NPI 1982785689
$6,096.15
in general payments reported to CMS, 2019-2025
25 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $561 · 2021: $613 · 2022: $540 · 2023: $1,279 · 2024: $1,270 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,113 · Education: $34.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,113.11 |
| Education | $34.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,582.30 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,363.97 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $561.56 | 2019-2024 | Ofev, Stiolto Respimat |
| W. L. Gore & Associates, INC. | $374.13 | 2021 | |
| Genzyme Corporation | $364.67 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.26 | 2023-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $223.95 | 2023-2025 | Dupixent |
| Insmed, INC. | $192.13 | 2023-2025 | Arikayce, Brinsupri |
| Baxter Healthcare | $185.93 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System, Hillrom - Monarch Airway Clearance System |
| Amgen INC. | $168.05 | 2022-2025 | Tezspire |
| Philips North America LLC | $157.50 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Inogen, INC. | $136.97 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Actelion Pharmaceuticals US, INC. | $81.55 | 2022-2024 | Uptravi, Opsumit |
| Verona Pharma, INC. | $77.23 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $68.51 | 2022-2025 | Zerbaxa, Winrevair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $62.29 | 2019-2024 | Xarelto |
| Grifols USA, LLC | $53.19 | 2020-2025 | Prolastin-C Liquid |
| Fisher & Paykel Healthcare INC | $32.80 | 2024 | Fisher & Paykel Healthcare |
| Bayer Healthcare Pharmaceuticals INC. | $32.53 | 2019-2020 | |
| Pulmonx Corporation | $27.02 | 2022 | |
| Inspire Medical Systems, INC. | $26.98 | 2024 | Inspire |
| Abbvie INC. | $25.56 | 2022 | |
| Caris Mpi, INC. | $24.59 | 2025 | Mi Cancer Seek |
| United Therapeutics Corporation | $23.52 | 2021 | |
| Csl Behring | $18.96 | 2023 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Adelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.